• Explore /
  • Poster
  • / A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.

Abstract Poster

Authors

null

Pei Shu

Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China

Pei Shu , Xiaoyu Li , Li Yuan , Qi Zhou , Guiling Li , Keqiang Zhang , Hui Xie , Yongsheng Wang , Qiu Li , Li Zheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT04337463

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2526)

DOI

10.1200/JCO.2023.41.16_suppl.2526

Abstract #

2526

Poster Bd #

368

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Jiaxin Niu

First Author: Gerald Steven Falchook

First Author: Jayesh Desai